Primaa

Deep learning image analysis is the entire offering. Cleo Breast and Cleo Skin are algorithms that detect and quantify biomarkers in whole slide images, with no viewer, scanner, or laboratory of the company's own. The deliberate choice to integrate into other vendors' platforms rather than build a workspace confirms the model: the company sells algorithms, not infrastructure.

Assistive by design and, unusually, measured as such. Cleo Breast is described as automated diagnostic support complementing pathologist expertise, and the dermatopathology validation study was structured specifically to compare pathologist performance with and without access to the AI, which treats the human plus machine pairing as the unit of evaluation rather than testing the algorithm alone. That study design is itself the strongest evidence of a genuine assistive posture, since it presumes the pathologist remains the decision maker.

Product function is described concretely, including which biomarkers Cleo Breast addresses and named capabilities such as mitosis and lymph node metastasis detection, and the company states clinical development was conducted with European reference laboratories. What is not published is training data scale or composition, model architecture, or performance figures, and the completed results of the dermatopathology validation study were still pending at the time of review. Clear about what the products do, quiet about how well and on what basis.

Evidence generation is underway and structurally sound but not yet published. A clinical performance study for Cleo Breast was launched to evaluate biomarker detection performance, and a dermatopathology validation study for Cleo Skin began in late 2025 on the PathPresenter platform, comparing diagnostic efficiency and agreement with and without AI assistance. As of this review the full results were not yet available pending completion of all phases. CE-IVDR certification implies a clinical evidence dossier reviewed by a notified body, so evidence exists in the regulatory file, but the public peer reviewed record is thin compared to established competitors.

No specific PHI handling or data governance framework was located. Multi platform distribution across several partner environments means slide data may traverse different infrastructures depending on the route, making stewardship a per deployment question.

No HIPAA or BAA commitment was located. The company reports official entry into the United States market through platform partnerships, which makes US business associate terms a live question, but the posture is not published.

No SOC 2, ISO 27001, or equivalent attestation and no trust center were located in the materials reviewed.

Meaningful European authorization, no US clearance. Cleo Breast is CE-IVDR marked as a primary diagnostic solution and, per the company, transitioned from the earlier standard to full IVDR compliance, while Cleo Skin is described as the first AI tool for dermatopathology to receive CE-IVDR certification, which if accurate is a genuine first in a specialty with little AI presence. No FDA clearance was located; US market entry is via platform partnerships rather than independent clearance. One scope caveat a buyer should catch: in the AISight integration the company itself lists Cleo Breast as CE-IVDR and Cleo Skin as research use only, so the regulatory status of the skin product depends on the market and route.

No formal governance framework, monitoring commitment, or demographic subgroup analysis was located. Skin pathology carries a well documented performance concern across skin tones in adjacent AI fields, which makes the absence of published subgroup analysis for a dermatopathology product particularly worth pressing on.

The clearest multi platform integration strategy of any algorithm only vendor in this index. Cleo runs inside PathAI's AISight, Proscia, PathPresenter, and Gestalt environments, and the breast product is described as integrating into existing viewers such as Sectra. Three of those hosts are separately indexed here. For a laboratory, this means adoption is likely a matter of enabling an algorithm in a workspace already deployed rather than running an integration project, and it reduces the platform lock in risk that comes with single host algorithms. This is the laboratory image environment rather than the EHR.

No hosting, tenancy, or data residency terms were located. Because the algorithms run inside partner platforms, residency is effectively determined by whichever host environment the laboratory uses rather than by this vendor.

No pricing is published. The multi platform distribution model means commercial terms likely vary by host environment, and the company discloses corporate milestones such as a pre Series A round rather than product economics. A buyer should establish which platform route they are purchasing through and whether the license covers Cleo Breast, Cleo Skin, or both, given their differing regulatory status.

Two specialties, one of them genuinely underserved. Breast pathology is the most crowded application in pathology AI, but dermatopathology has very little AI presence, and the company positions Cleo Skin as the first CE-IVDR certified tool in that specialty. A stated multi organ roadmap suggests intended expansion. Narrow today, but the dermatopathology position is differentiated rather than duplicative.